Paper Details

  1. Home
  2. Paper Details

Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.

Author: BreithardtGünter, DeusterOliver, FernerMarion, KonradTorsten, MeinertzThomas, MünzelThomas, RostockThomas, Seibert-GrafeMonika, WachtlinDaniel, von BardelebenStephan

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dabigatran etexilate is an effective oral anticoagulant for the prevention of thromboembolic events in patients with atrial fibrillation. However, there is limited evidence on its efficacy and safety for the resolution of left atrial appendage thrombi.
Paper Details　
Original Abstract of the Article :
Dabigatran etexilate, a direct thrombin inhibitor and non-vitamin K antagonist oral anticoagulant (NOAC), has been shown to effectively prevent thromboembolic events in patients with non-valvular atrial fibrillation (AF). However, there is a paucity of data on the antithrombotic efficacy and safety ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00392-015-0883-7

データ提供：米国国立医学図書館（NLM）

A New Approach to Treating Atrial Fibrillation

Atrial fibrillation, a common heart rhythm disorder, is like a desert wind that can disrupt the smooth flow of life. This study delves into the potential of dabigatran etexilate, a direct thrombin inhibitor, in treating atrial fibrillation.

The authors are investigating the efficacy and safety of dabigatran in the resolution of left atrial appendage (LAA) thrombi in patients with atrial fibrillation. They aim to shed light on its potential to effectively prevent thromboembolic events. Imagine dabigatran as a calming oasis in the desert of atrial fibrillation, offering a potential treatment for this debilitating condition.

Dabigatran: A Promising Treatment for Atrial Fibrillation

This research highlights the potential of dabigatran etexilate in treating atrial fibrillation. The study's design and rationale underscore the need for further exploration of this promising drug. It's like finding a hidden trail through the desert, leading to a new and potentially effective treatment.

Living With Atrial Fibrillation: Staying Healthy and Informed

The study of dabigatran etexilate offers hope for improved treatment options for patients with atrial fibrillation. It is important to stay informed about advancements in medical treatments and discuss them with qualified healthcare professionals. Just like a desert traveler needs to be aware of the terrain, we need to be vigilant about our health and seek appropriate medical guidance.

Dr.Camel's Conclusion

The search for effective treatments for atrial fibrillation continues. This study sheds light on the potential of dabigatran etexilate, offering hope for new therapeutic avenues in managing this complex condition. As researchers, we must continue our quest to navigate the desert of medical challenges and bring forth innovative solutions.

Date :
  1. Date Completed 2016-10-31
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26109251

DOI: Digital Object Identifier

10.1007/s00392-015-0883-7

Related Literature

Article Analysis
・Effects of dabigatran
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.